Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 2, 2013, Pages

  Blich, Miry ^a   Golan, Amnon ^a   Arvatz, Gil ^a   Sebbag, Anat ^a   Shafat, Itay ^a   Sabo, Edmond ^b   Cohen Kaplan, Victoria ^a   Petcherski, Sirouch ^a   Avniel Polak, Shani ^c   Eitan, Amnon ^a   Hammerman, Haim ^a   Aronson, Doron ^a   Axelman, Elena ^a   Ilan, Neta ^a   Nussbaum, Gabriel ^c   Vlodavsky, Israel ^a  

^a Pathology Rambam Health Care Campus ^*

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

heparanase; macrophages; TLR; TNF ; vulnerable plaque

Indexed keywords

GELATINASE B; HEPARANASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ANIMAL CELL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STABLE ANGINA PECTORIS;

ANGINA, STABLE; ANIMALS; ATHEROSCLEROSIS; CELL LINE; CHEMOKINE CCL2; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC; POLYMERASE CHAIN REACTION; RUPTURE, SPONTANEOUS; SIGNAL TRANSDUCTION; TIME FACTORS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872945553     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.254961     Document Type: Article

References (66)

1. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A defni-tion of advanced types of atherosclerotic lesions and a histological clas-sifcation of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355-1374.
2. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classifca-tion scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262-1275.
3. Virmani R, Burke A P, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47(Suppl 8):C13-C18.
4. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological signifcance and molecular basis. Atherosclerosis. 1998;139:205-222.
5. Williams KJ, Tabas I. The response-to-retention hypothesis of early ath-erogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551-561.
6. Castellot JJ Jr, Addonizio ML, Rosenberg R, Karnovsky MJ. Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol. 1981;90:372-379.
7. Nugent MA, Nugent HM, Iozzo RV, Sanchack K, Edelman ER. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA. 2000;97:6722-6727.
8. Tran-Lundmark K, Tran PK, Paulsson-Berne G, Fridén V, Soininen R, Tryggvason K, Wight TN, Kinsella MG, Borén J, Hedin U. Heparan sul-fate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ Res. 2008;103:43-52.
9. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001;1471:M99-108.
10. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001;108:341-347.
11. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical signif-cance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006;38:2018-2039.
12. Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med. 2007;11:427-452.
13. Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, Steinkühler C. Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry. 2004;43:1862-1873.
14. Vlodavsky I. Preparation of extracellular matrices produced by cultured corneal endothelial and PF-HR9 endodermal cells. In: Bonifacino JS, Hartford JB, Lippincott-Schwartz J, Yamada KM, eds. Protocols in Cell Biology. New York, NY: John Wiley & Sons; 1999.
15. Nussbaum G, Ben-Adi S, Genzler T, Sela M, Rosen G. Involvement of Toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath components. Infect Immun. 2009;77:3939-3947.
16. Nagler A, Shur I, Barak V, Fabian I. Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autol-ogous bone marrow transplantation. Leuk Res. 1996;20:637-643.
17. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C, Vlodavsky I, Ilan N. Structure-function approach identifes a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 2009;69:1758-1767.
18. Barash U, Cohen-Kaplan V, Arvatz G, Gingis-Velitski S, Levy-Adam F, Nativ O, Shemesh R, Ayalon-Sofer M, Ilan N, Vlodavsky I. A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J. 2010;24:1239-1248.
19. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, Ilan N. Heparanase augments epidermal growth factor receptor phosphoryla-tion: correlation with head and neck tumor progression. Cancer Res. 2008;68:10077-10085.
20. Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoreto M, Cassinelli G, Lanzi C, Pisano C, Ilan N, Vlodavsky I, Zunino F. Pre-clinical and clinical signifcance of heparanase in Ewing's sarcoma. J Cell Mol Med. 2011;15:1857-1864.
21. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman M Y, Vlodavsky I, Ilan N. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci. 2004;117(Pt 11):2249-2258.
22. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocar-dial infarction. N Engl J Med. 2000;343:915-922.
23. Shafat I, Barak AB, Postovsky S, Elhasid R, Ilan N, Vlodavsky I, Arush MW. Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia. 2007;9:909-916.
24. Shafat I, Ilan N, Zoabi S, Vlodavsky I, Nakhoul F. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels. PLoS ONE. 2011;6:e17312.
25. Shafat I, Vlodavsky I, Ilan N. Characterization of mechanisms involved in secretion of active heparanase. J Biol Chem. 2006;281:23804-23811.
26. Baker AB, Groothuis A, Jonas M, Ettenson DS, Shazly T, Zcharia E, Vlodavsky I, Seifert P, Edelman ER. Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res. 2009;104:380-387.
27. Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE, Parish CR. Identifcation of active-site residues of the pro-metastatic endoglyco-sidase heparanase. Biochemistry. 2000;39:15659-15667.
28. Gingis-Velitski S, Zetser A, Kaplan V, Ben-Zaken O, Cohen E, Levy-Adam F, Bashenko Y, Flugelman MY, Vlodavsky I, Ilan N. Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J Biol Chem. 2004;279:44084-44092.
29. Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem Sci. 2009;34:511-519.
30. Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res. 2004;61:671-682.
31. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol. 2001;38:307-314.
32. Martin MU, Wesche H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim Biophys Acta. 2002;1592:265-280.
33. Doyle SL, O'Neill LA. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol. 2006;72:1102-1113.
34. Hansson GK. Infammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
35. Fitzgerald M, Hayward IP, Thomas AC, Campbell GR, Campbell JH. Matrix metalloproteinase can facilitate the heparanase-induced promotion of phenotype change in vascular smooth muscle cells. Atherosclerosis. 1999;145:97-106.
36. Planer D, Metzger S, Zcharia E, Wexler ID, Vlodavsky I, Chajek-Shaul T. Role of heparanase on hepatic uptake of intestinal derived lipoprotein and fatty streak formation in mice. PLoS ONE. 2011;6:e18370.
37. Baker AB, Chatzizisis YS, Beigel R, Jonas M, Stone BV, Coskun AU, Maynard C, Rogers C, Koskinas KC, Feldman CL, Stone PH, Edelman ER. Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine. Atherosclerosis. 2010;213:436-442.
38. Baker AB, Gibson WJ, Kolachalama VB, Golomb M, Indolf L, Spruell C, Zcharia E, Vlodavsky I, Edelman ER. Heparanase regulates thrombosis in vascular injury and stent-induced fow disturbance. J Am Coll Cardiol. 2012;59:1551-1560.
39. Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica. 2010;95:1927-1934.
40. Nadir Y, Brenner B, Zetser A, Ilan N, Shafat I, Zcharia E, Goldshmidt O, Vlodavsky I. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost. 2006;4:2443-2451.
41. Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol. 2005;3:63-68.
42. Ikeda U. Infammation and coronary artery disease. Curr Vasc Pharmacol. 2003;1:65-70.
43. Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V, Rubinstein AM, Ishai-Michaeli R, Atzmon R, Sherman Y, Meirovitz A, Peretz T, Vlodavsky I, Elkin M. Heparanase powers a chronic infamma-tory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest. 2011;121:1709-1721.
44. Chen G, Wang D, Vikramadithyan R, Yagyu H, Saxena U, Pillarisetti S, Goldberg IJ. Infammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry. 2004;43:4971-4977.
45. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem. 2008;283:32628-32636.
46. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 2003;63: 8749-8756.
47. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I, Abramovitch R. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer. 2006;118:1609-1617.
48. Doviner V, Maly B, Kaplan V, Gingis-Velitski S, Ilan N, Vlodavsky I, Sherman Y. Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol. 2006;19:878-888.
49. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006;66:1455-1463.
50. Zetser A, Bashenko Y, Miao HQ, Vlodavsky I, Ilan N. Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res. 2003;63:7733-7741.
51. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, Vlodavsky I. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 2001;15:1661-1663.
52. Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S, Sarid R, Naggi A, Casu B, Ilan N, Vlodavsky I, Abramovitch R. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J. 2005;19:211-221.
53. Myler HA, West JL. Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. J Biochem. 2002;131:913-922.
54. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373-384.
55. Cole JE, Georgiou E, Monaco C. The expression and functions of tolllike receptors in atherosclerosis. Mediators Infamm. 2010;2010:393946.
56. Levy-Adam F, Ilan N, Vlodavsky I. Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol. 2010;20:153-160.
57. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev. 2005;204:27-42.
58. Brunn GJ, Bungum MK, Johnson GB, Platt JL. Conditional signaling by Toll-like receptor 4. FASEB J. 2005;19:872-874.
59. Merline R, Moreth K, Beckmann J, Nastase M V, Zeng-Brouwers J, Tralhão JG, Lemarchand P, Pfeilschifter J, Schaefer RM, Iozzo RV, Schaefer L. Signaling by the matrix proteoglycan decorin controls infammation and cancer through PDCD4 and MicroRNA-21. Sci Signal. 2011;4:ra75.
60. Schaefer L, Iozzo RV. Small leucine-rich proteoglycans, at the crossroad of cancer growth and infammation. Curr Opin Genet Dev. 2012;22:56-57.
61. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol. 2006;177:1272-1281.
62. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457:102-106.
63. Levy-Adam F, Abboud-Jarrous G, Guerrini M, Beccati D, Vlodavsky I, Ilan N. Identifcation and characterization of heparin/heparan sul-fate binding domains of the endoglycosidase heparanase. J Biol Chem. 2005;280:20457-20466.
64. Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-Michaeli R, Vlodavsky I. Modulation of the heparanase-inhibiting activity of heparin through selective desul-fation, graded N-acetylation, and glycol splitting. J Biol Chem. 2005;280:12103-12113.
65. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 2007;13:2057-2073.
66. Myler HA, Lipke EA, Rice EE, West JL. Novel heparanase-inhibiting antibody reduces neointima formation. J Biochem. 2006;139:339-345.